Sidra Medicine and İzmir Biomedicine and Genome Center (IBG) Sign MoU to Advance Pediatric Biomedical Research
Strengthening Collaboration in Genomics, Precision Medicine, and Translational Research 18 March 2025, Doha, Qatar – Sidra Medicine, a member of Qatar Foundation, has signed a Memorandum of Understanding (MoU) with the İzmir Biomedicine and Genome Center (IBG) to enhance collaboration in pediatric biomedical research. The agreement marks a significant milestone in fostering scientific research, innovation, and knowledge exchange between the two institutions. Dr. Iyabo Tinubu-Karch, Chief Executive Officer at Sidra Medicine, emphasized the significance of the partnership, stating: “The MoU with IBG is a major step in accelerating genomic discoveries for rare diseases. Our collaboration will focus on key areas including biobanking, genomics and multi-omics, bioinformatics, animal models of disease, and stem cell research. By working together, we aim to advance precision medicine and develop groundbreaking solutions for children with complex medical conditions.” Prof. Yılmaz, Director of IBG, said: “Partnering with Sidra Medicine, a globally recognized leader in pediatric healthcare and research, reinforces our commitment to advancing biomedical research. This collaboration will enable us to make meaningful strides in genomic and translational medicine, ultimately improving healthcare outcomes for children globally.” The partnership with IBG will also establish a framework for collaborative research projects, academic exchanges, and the sharing of expertise in key areas such as genomics, precision medicine, and translational research. By combining resources and knowledge, Sidra Medicine and IBG aim to address critical health challenges affecting children worldwide. Prof. Khalid Fakhro, Chief Research Officer at Sidra Medicine said: “Our agreement with IBG will also enable student exchanges and visiting scientist programs in both directions between Qatar and Turkey, as well as joint grant applications. Additionally, we will establish research cohorts with similar disorders across the MENAT region, helping us gain deeper insights into disease patterns and therapeutic interventions.” The agreement paves the way for future joint initiatives, including research collaborations, training programs, and knowledge-sharing efforts that will benefit both institutions and the broader scientific community.
Visit Qatar signs MoU with Microsoft at Web Summit Qatar 2025 to advance smart tourism solutions
Visit Qatar and Microsoft have formalised their collaboration to drive digital innovation in tourism with a Memorandum of Understanding (MoU) signed at Web Summit Qatar 2025 on 25th February. The MoU was signed by Eng. Abdulaziz Ali Al-Mawlawi, CEO of Visit Qatar, and Lana Khalaf, Country Manager of Microsoft, marking the next phase of this partnership. Leveraging the success of the Visit Qatar GenAI Travel Concierge, powered by Microsoft Azure and OpenAI 4o and 4o mini, both entities will explore cutting-edge technologies to enhance visitor experiences and transform business operations. The Smart Travel Assistant from Visit Qatar is a pioneering innovation that seamlessly integrates text, voice, content, a conversational virtual assistant, maps, and an interactive planning interface. This innovation has set new standards for digital excellence in tourism. Visit Qatar and Microsoft are working on developing a comprehensive technology roadmap that aims to enhance the visitor experience through integrated smart and digital solutions.
